Company Overview of Ontario Institute For Cancer Research
101 College St Suite 800
Toronto, ON M5g 1l7
Founded in 2001
Key Executives for Ontario Institute For Cancer Research
President and Scientific Director
Deputy Director and Chief Scientific Officer
Compensation as of Fiscal Year 2016.
Ontario Institute For Cancer Research Key Developments
Researchers At the Ontario Institute for Cancer Research, University Health Network and Eastern Virginia Medical School Discover Protein Signatures for Accurate Non-Invasive Diagnosis of Aggressive Prostate Cancer
Jun 28 16
Researchers at the Ontario Institute for Cancer Research (OICR) and University Health Network (UHN), along with researchers at the Eastern Virginia Medical School, have created protein signatures that accurately diagnose prostate cancer and can distinguish between patients with aggressive versus non-aggressive disease using a simple urine sample. The findings could be developed into a non-invasive "liquid biopsy" that could provide a faster, cheaper and easier method to detect prostate cancer with fewer complications for patients. The findings were published on June 28, 2016 in the journal Nature Communications. Researchers performed an initial discovery screen on urine samples from men who were diagnosed with prostate cancer and those who were not to look for all proteins that might be different between them. They also screened for all proteins in the urine that might be different between patients with aggressive and non-aggressive disease. From these initial discoveries, they identified a subset of proteins unique to each grouping and developed two signatures: one that could be used to accurately indicate whether a patient has prostate cancer or not and a separate signature to indicate outcome. Current methods to diagnose prostate cancer usually include a combination of digital rectal exams, prostate specific antigen (PSA) tests and biopsy, all of which have drawbacks, including their invasiveness for patients, potential complications and false-positive results (tests finding evidence of cancer when none is there). Finding new ways to accurately diagnose prostate cancer is considered a priority for many research institutions, including OICR, because the result of these tests' shortcomings is in many cases over-diagnosis and over-treatment. There were three sites involved in the discovery and each brought their own unique expertise to the project. The Eastern Virginia Medical School developed clinical resources, while UHN researchers were generating large amounts of proteomic data and were developing new techniques to test proteins in blood. All of the proteomic and clinical data flowed to OICR where it was pieced together using computational biology, and where the proteins in the discovery screen were identified. The study has to date gone through development and initial validation and it is now ready for a large retrospective validation study, which the collaborators are now designing. After validation is successfully completed it would then move into clinical trials.
The Ontario Institute for Cancer Research and Novera Therapeutics Collaborate with Janssen Biotech
Oct 16 15
The Ontario Institute for Cancer Research and Novera Therapeutics have collaborated with Johnson & Johnson's Janssen Biotech. The collaboration is aimed at accelerating the development of small molecule drugs for haematological cancers. By collaborating with University Health Network, Novera intends to discover and develop novel therapeutic compounds identified through Ontario Institute for Cancer Research's drug discovery programme. The firm will coordinate the partnership with Janssen under a license option and exclusive license agreement. The contract will see Novera receive an upfront payment and make it eligible to receive various pre-clinical, clinical, regulatory and commercialisation payments up to a total of around CAD 450 million. Janssen Biotech has been granted an exclusive option to license candidate drugs that have been identified through the collaboration, for all human uses globally. The firm will also manage responsibility for subsequent pre-clinical, clinical and commercial development upon exercising of its option. Under the collaboration, The Ontario Institute for Cancer Research will identify, fund and support oncology innovations in a bid to improve clinical practice.
Ontario Institute for Cancer Research Extends Collaboration with Janssen Inc. to Develop Clinical Trials for Prostate Cancer
Feb 25 15
The Ontario Institute for Cancer Research (OICR) is extending its collaborative research partnership with Janssen Inc. to develop more multi-centre clinical trials and other translational research projects that address important clinical questions in prostate cancer. The new funds will be made available to qualifying researchers at cancer centres across Canada who are addressing important clinical questions in prostate cancer. The funding will be dispersed to researchers through the Canadian Cancer Clinical Trials Network, which is based at OICR, through an open application process.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries